Ventures Vi, Llc Vivo Ventu... Net Worth

The estimated Net Worth of Ventures Vi, Llc Vivo Ventu... is at least $22.4 mil dollars as of 18 August 2016. Ventures Ventu owns over 187,500 units of Eiger BioPharmaceuticals Inc stock worth over $22,418 and over the last 8 years Ventures sold EIGR stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ventures Ventu EIGR stock SEC Form 4 insiders trading

Ventures has made over 1 trades of the Eiger BioPharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Ventures bought 187,500 units of EIGR stock worth $3,000,000 on 18 August 2016.

The largest trade Ventures's ever made was buying 187,500 units of Eiger BioPharmaceuticals Inc stock on 18 August 2016 worth over $3,000,000. On average, Ventures trades about 187,500 units every 0 days since 2016. As of 18 August 2016 Ventures still owns at least 12,996 units of Eiger BioPharmaceuticals Inc stock.

You can see the complete history of Ventures Ventu stock trades at the bottom of the page.

Insiders trading at Eiger BioPharmaceuticals Inc

Over the last 9 years, insiders at Eiger BioPharmaceuticals Inc have traded over $3,017,304 worth of Eiger BioPharmaceuticals Inc stock and bought 780,533 units worth $4,706,203 . The most active insiders traders include Richard A Kayne, Edgar Engleman, ePartners X Lp Inter West Ma.... On average, Eiger BioPharmaceuticals Inc executives and independent directors trade stock every 70 days with the average trade being worth of $47,232. The most recent stock trade was executed by Richard A Kayne on 31 October 2023, trading 278,239 units of EIGR stock currently worth $72,342.

What does Eiger BioPharmaceuticals Inc do?

eiger inc is a research company located in 500 crescent ct ste 300, dallas, texas, united states.

Complete history of Ventures Ventu stock trades at Eiger BioPharmaceuticals Inc

Eiger BioPharmaceuticals Inc executives and stock owners

Eiger BioPharmaceuticals Inc executives and other stock owners filed with the SEC include:

• David Cory,
  President, Chief Executive Officer, Director
• David Apelian,
  Director
• Stephana Patton,
  Chief Compliance Officer, General Counsel, Corporate Secretary
• Sriram Ryali,
  Chief Financial Officer
• David A. Cory M.B.A., R.Ph., R.Ph, MBA,
  Bus. Founder, Pres, CEO & Director
• James Shaffer,
  Chief Business Officer
• David A. Cory R.Ph, MBA,
  Bus. Founder, Pres, CEO & Director
• Eldon C. Mayer III, M.B.A.,
  Exec. VP & Chief Commercial Officer
• Sriram Ryali M.B.A.,
  Chief Financial Officer
• Christine Murray,
  Independent Director
• Thomas Dietz,
  Independent Chairman of the Board
• Amit Sachdev,
  Independent Director
• Evan Loh,
  Independent Director
• Eldon Mayer,
  Executive Vice President, Chief Commercial Officer
• Jeffrey Glenn,
  Independent Director
• Dr. Evan Loh,
  CEO of Paratek Pharmaceuticals & Director
• Dr. Jeffrey S. Glenn,
  Founder, Scientific Advisor & Independent Director
• Dr. Stephana E. Patton J.D., Ph.D.,
  Consultant
• Erik Atkisson,
  Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Dr. Colin Hislop,
  Sr. VP of Clinical & Devel. Operations
• Rich Franco M.B.A.,
  Sr. VP & Progeria Program Lead
• Dr. Ingrid C. Choong,
  Sr. VP of Clinical Devel.
• Charles Bramlage,
  Director
• Edgar Engleman,
  Director
• Joanne Quan,
  Chief Medical Officer
• Eduardo Bruno Martins,
  SVP, Liver and Infectious Dise
• Ventures Vi, Llc Vivo Ventu...,
  
• James H Welch,
  Chief Financial Officer
• Nina S Kjellson,
  Director
• Kim Sablich,
  
• Partners X Lp Inter West Ma...,
  
• Ingrid Choong,
  Chief Business Officer
• Erik Atkisson,
  GC & Chief Compliance Officer
• Lisa Kelly Croswell,
  
• James Vollins,
  General Counsel
• Leen Kawas,
  
• Richard A Kayne,